Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Masahiro Tabata

Phase II Trial of Gefitinib in Combination With Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer With Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

Journal of Thoracic Oncology

English

Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients With Non-Small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience

Journal of Thoracic Oncology

English

MET or NRAS Amplification Is an Acquired Resistance Mechanism to the Third-Generation EGFR Inhibitor Naquotinib

Scientific Reports

Multidisciplinary

2018

English

Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systemic Review

PLoS ONE

Multidisciplinary

2011

English

A Prospective Cohort Study to Define the Clinical and Pathological Features of Lung Cancers Harboring HER2 Gene Aberrations (The HER2-CS Study) and a Phase II Study of Trastuzumab Emtansine (Recombinant) in Patients With HER2-positive Non-Small Cell Lung Cancer Who Recurred, Progressed After Standard Chemotherapy, or Were Primarily Refractory to Standard Chemotherapy

Okayama Igakkai Zasshi (Journal of Okayama Medical Association)

2015

English

Point Mutation of K-Ras Gene in Cisplatin-Induced Lung Tumours in a/J Mice

English

Gefitinib Induces Premature Senescence in Non-Small Cell Lung Cancer Cells With or Without EGFR Gene Mutation

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Masahiro Tabata

Phase II Trial of Gefitinib in Combination With Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer With Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients With Non-Small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience

MET or NRAS Amplification Is an Acquired Resistance Mechanism to the Third-Generation EGFR Inhibitor Naquotinib

Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systemic Review

Point Mutation of K-Ras Gene in Cisplatin-Induced Lung Tumours in a/J Mice

Gefitinib Induces Premature Senescence in Non-Small Cell Lung Cancer Cells With or Without EGFR Gene Mutation